Matrix metalloproteinase expression during experimental autoimmune neuritis

Brain : a Journal of Neurology
P M HughesK M Miller

Abstract

Experimental autoimmune neuritis (EAN) is an animal model of Guillain-Barré syndrome. We have shown recently that BB-1101, a broad-spectrum matrix metalloproteinase (MMP) inhibitor, prevents development of EAN when given from the day of immunization and, more important clinically, reduces disease severity when given from symptom onset. This suggests the involvement of MMP activity in the pathogenesis of EAN. However, the exact function and expression patterns of MMPs in acute inflammation of the PNS have not been investigated. MMP-like enzymes are also involved in the processing of tumour necrosis factor-alpha (TNF-alpha), which has been implicated previously in the pathology associated with EAN. In the present study we investigated the profile of MMP and TNF-alpha expression and their localization in sciatic nerve tissue during EAN, using a semiquantitative competitive reverse transcriptase-coupled polymerase chain reaction and immunohistochemistry. In the normal rat PNS, four of the 10 MMPs studied were constitutively expressed and four MMPs were differentially regulated during EAN. Expression of TNF-alpha was elevated at peak disease severity and localized to Schwann cells, macrophages and endoneurial blood vessels. Expressi...Continue Reading

Citations

Nov 26, 2002·Journal of Neuroimmunology·M LauràR A C Hughes
May 14, 2003·Journal of Neuroimmunology·Catharina M P VosHelga E de Vries
Mar 1, 2000·Journal of Neuroimmunology·R A HughesK J Smith
Mar 10, 2001·Progress in Neurobiology·R KieferH P Hartung
Jun 14, 2002·Neuromuscular Disorders : NMD·Mathias MäurerRalf Gold
Apr 6, 2007·Nature Clinical Practice. Neurology·Gerd Meyer zu HörsteBernd C Kieseier
Mar 6, 2002·Clinical and Experimental Immunology·A Faber-ElmannE Mozes
Oct 28, 2008·Brain : a Journal of Neurology·Aurélie Lonigro, Jérôme J Devaux
Jul 23, 1999·Annals of the New York Academy of Sciences·M DemestreR A Hughes
Nov 24, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·A Créange
Nov 3, 2005·American Journal of Veterinary Research·Kara C SorensenArthur M Siegel
Dec 14, 1999·Clinical and Experimental Immunology·G R WallaceJ M Clements
Jun 6, 2013·Mediators of Inflammation·David H TianGila Moalem-Taylor
Jun 10, 2011·Neurochemical Research·Chenju YiZhiren Zhang
Aug 31, 2002·Glia·Gary A Rosenberg
Dec 16, 1998·Current Opinion in Neurology·H P HartungJ D Pollard
Sep 2, 1998·Current Opinion in Neurology·A J SteckH P Hartung
Nov 4, 2000·Expert Opinion on Investigational Drugs·J Pritchard
Nov 2, 2015·The Journal of Surgical Research·Elif Basaran GundogduMehmet Cansev
Jan 26, 2010·Biochemical and Biophysical Research Communications·Xiu Li ZhaoDi Zhong
Apr 10, 2014·The Journal of Investigative Dermatology·Angela TewariAntony R Young
Sep 27, 2008·Molecular and Cellular Neurosciences·Hideo KobayashiVeronica I Shubayev
Sep 10, 2005·Neuropathology and Applied Neurobiology·M DemestreN A Gregson
Apr 6, 2007·Muscle & Nerve·Susanne Renaud, David Leppert
Sep 18, 2007·Journal of the Peripheral Nervous System : JPNS·Rosane M B TelesEuzenir N Sarno
Apr 11, 2008·Journal of Cellular and Molecular Medicine·Zhi-Yuan ZhangHermann J Schluesener
Oct 12, 2010·Journal of Neuroscience Research·Kishan K NyatiVimal K Paliwal
Nov 22, 2005·Molecular and Cellular Neurosciences·Veronica I ShubayevRobert R Myers
Oct 17, 2009·Molecular Immunology·Valeria RamagliaFrank Baas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.